Lilly to collaborate with Hanmi on RA drug
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co is building out its autoimmune pipeline with a deal that could be worth $690m to Korea's Hanmi Pharmaceuticals, the companies announced 19 March.